COVID-19 vaccines can affect liver enzymes, but it happens rarely. In a large study of over 470,000 vaccinated people, only 0.038% developed meaningful liver injury within 12 weeks of receiving a dose. That works out to roughly 1 in 2,600 people. For the vast majority, liver function stays completely normal after vaccination.
If you recently had blood work showing elevated liver enzymes after a COVID shot, here’s what the research says about why it happens, what it looks like, and what to expect.
How Common Liver Enzyme Elevations Are
The best data comes from a study published in the Journal of Hepatology that tracked nearly half a million vaccinated individuals and carefully excluded other causes of liver problems, including hepatitis B and C, alcohol use, medications known to stress the liver, and recent hospitalizations. After filtering all of that out, 177 people (0.038%) met the threshold for liver injury, defined as ALT above 200, alkaline phosphatase above 250, or bilirubin above 2.5 mg/dl on at least two consecutive tests.
For context, normal ALT typically falls between 0 and 45 IU/L, and normal AST between 0 and 35 IU/L. Among the small group who did develop liver injury, the average peak ALT was 553 IU/L and the average peak AST was 800 IU/L. Those are significant elevations, but they occurred in a tiny fraction of vaccinated people.
Why It Happens
The leading explanation is an immune-mediated reaction, meaning the body’s own immune response to the vaccine inadvertently targets liver cells. Several pathways have been proposed.
The most discussed is molecular mimicry. The spike protein produced after vaccination shares structural similarities with certain proteins found on liver cells. The immune system, activated to attack the spike protein, may accidentally cross-react with those liver proteins. This can trigger immune cells and antibodies to inflict collateral damage on the liver.
The delivery systems used in the vaccines also play a role in the inflammatory environment. The lipid nanoparticles in mRNA vaccines and the viral vectors in other formulations can activate parts of the innate immune system, potentially pushing the immune response beyond what’s needed. In some susceptible individuals, this stronger-than-usual inflammation spills over into liver tissue.
A third proposed mechanism involves a loss of immune self-tolerance, where the vaccine’s inflammatory signals activate pathways that lower the immune system’s normal restraint against attacking the body’s own cells. This can produce a presentation that closely resembles autoimmune hepatitis, complete with specific autoantibodies and a pattern of inflammation visible on liver biopsy.
What It Looks Like Clinically
When liver injury does occur after vaccination, it tends to present within the first 12 weeks after the first or second dose. In documented cases, patients developed jaundice (yellowing of skin or eyes), fatigue, and blood work showing dramatically elevated liver enzymes. Liver biopsies in these patients showed inflammation around the portal areas of the liver, clusters of immune cells called plasma cells, and signs of liver cell death.
About 29% of affected individuals had elevated bilirubin levels above 2.5 mg/dl, which is the threshold where jaundice becomes visible. In one well-documented case, a patient’s ALT reached 1,701 IU/L, roughly 38 times the upper limit of normal, with a bilirubin level high enough to meet criteria for serious liver injury. That patient tested positive for autoantibodies commonly associated with autoimmune hepatitis.
Vaccine Type Does Not Seem to Matter
A multicenter study published in Hepatology compared liver injury patterns across the three major vaccine platforms: Pfizer-BioNTech (mRNA), Moderna (mRNA), and Oxford-AstraZeneca (viral vector). The rates of immune-mediated liver injury were statistically indistinguishable: 59.6% of Pfizer cases, 55.6% of AstraZeneca cases, and 50% of Moderna cases showed an immune-mediated pattern. Peak enzyme elevations were also similar across all three. The researchers concluded that no single vaccine type carried a higher liver risk than the others.
How These Cases Are Treated
The good news is that vaccine-related liver enzyme elevations generally respond well to treatment. Roughly half to two-thirds of documented cases were treated with corticosteroids, which suppress the overactive immune response. In case reports, patients showed rapid improvement in both symptoms and lab values after starting steroid therapy. Treatment response and outcomes were similar regardless of which vaccine the patient had received.
One feature that helps distinguish vaccine-related liver injury from true autoimmune hepatitis is the long-term outlook. Classic autoimmune hepatitis tends to relapse when immunosuppressive medication is stopped. Vaccine-triggered cases, by contrast, often resolve without relapsing after treatment ends, suggesting the immune trigger was temporary rather than an ongoing autoimmune process. Liver biopsies in these patients typically show early, recent fibrosis rather than the advanced scarring seen in chronic liver disease.
What Mildly Elevated Enzymes After Vaccination Mean
Most people searching this topic are probably not in the severe category described above. A mildly elevated ALT or AST on routine blood work, perhaps 50 to 100 IU/L, is a much more common and less concerning scenario. Mild, transient elevations can occur with any strong immune activation, including viral infections, intense exercise, or new medications. If your levels are only slightly above normal, the most likely outcome is that they return to baseline on their own within a few weeks.
The pattern worth paying attention to is persistent or rapidly rising enzymes, especially if accompanied by symptoms like yellowing of the skin or eyes, dark urine, unusual fatigue, or abdominal pain in the upper right side. Those signs suggest the liver is under real stress and warrant follow-up blood work and possibly imaging or biopsy to rule out an immune-mediated reaction. The timing matters too: liver injury that appears within days to a few weeks of a vaccine dose fits the expected window for an immune-mediated process.